<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814654</url>
  </required_header>
  <id_info>
    <org_study_id>2018-9471</org_study_id>
    <nct_id>NCT04814654</nct_id>
  </id_info>
  <brief_title>CHALO! 2.0: A Mobile Technology Based Intervention to Accelerate HIV Testing and Linkage to Preventive Treatment.</brief_title>
  <official_title>CHALO! 2.0: A Mobile Technology Based Intervention to Accelerate HIV Testing and Linkage to Preventive Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Humsafar Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      While HIV prevalence among MSM in India is 10-15 times higher than in the general population&#xD;
      (4.3% vs 0.3%), current interventions for Indian MSM have limited reach. In order to reduce&#xD;
      the burden of HIV in MSM, innovative, far-reaching prevention and treatment strategies are&#xD;
      needed. Guided by the increase access to internet-based social and mobile technologies (SMT)&#xD;
      (e.g. SMS, WhatsApp, dating apps) globally and in India, this is a 3-arm parallel, pragmatic&#xD;
      randomized controlled trial of community-developed, theory based behavioral intervention&#xD;
      (CHALO! 2.0) delivered via WhatsApp (secure SMS application) compared to an Attention-Matched&#xD;
      Control, or a Digital Coupon for free HIV testing only control conditions. The primary&#xD;
      outcomes are HIV-testing at 6 months (3 months after the end of the intervention) and&#xD;
      linkage-to-preventive care (counseling or pre-exposure prophylaxis) at 12 months. The&#xD;
      secondary outcomes are the frequency of HIV-testing by 18 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 25, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV testing</measure>
    <time_frame>within six months from randomization</time_frame>
    <description>dichotomous measure (yes/no) of receipt of a verified HIV test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV testing</measure>
    <time_frame>within 12 months from randomization</time_frame>
    <description>dichotomous measure (yes/no) of receipt of a verified HIV test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Linkage to care</measure>
    <time_frame>within 12 months from randomization</time_frame>
    <description>a composite of linkage to PrEP, counseling, or HIV treatment (yes/no)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follow-up HIV testing</measure>
    <time_frame>within six months from randomization</time_frame>
    <description>self-reported HIV test (unverified)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linkage to PrEP</measure>
    <time_frame>within 12 months from randomization</time_frame>
    <description>a dichotomous measure (yes/no) of whether participants testing HIV negative sought out PrEP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linkage to HIV treatment</measure>
    <time_frame>within 12 months from randomization</time_frame>
    <description>a dichotomous measure (yes/no) of whether participants testing HIV positive sought out treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linkage to counseling</measure>
    <time_frame>within 12 months from randomization</time_frame>
    <description>a dichotomous measure (yes/no) of whether participants sought out counseling treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linkage to ART initiation</measure>
    <time_frame>within 12 months from randomization</time_frame>
    <description>a dichotomous measure (yes/no) of whether participants testing HIV positive initated ART treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up HIV testing</measure>
    <time_frame>within 18 months from randomization</time_frame>
    <description>frequency of HIV testing (verified)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linkage to care</measure>
    <time_frame>within 18 months from randomization</time_frame>
    <description>a composite of linkage to PrEP, counseling, or HIV treatment (yes/no)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>PEP use</measure>
    <time_frame>within six months from randomization</time_frame>
    <description>a dichotomous measure (yes/no) of whether a participant sought PEP treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>HIV testing</measure>
    <time_frame>within six months from randomization</time_frame>
    <description>a dichotomous measure (yes/no) of whether a participant intends to obtain an HIV test in the next one month</description>
  </other_outcome>
  <other_outcome>
    <measure>STI testing / treatment</measure>
    <time_frame>within six months from randomization</time_frame>
    <description>a dichotomous measure (yes/no) of whether a participant sought further STI testing or treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Type of site accessed</measure>
    <time_frame>within six months from randomization</time_frame>
    <description>Type of prevention or treatment care site accessed (i.e., Humsafar Trust, public institution, private institution)</description>
  </other_outcome>
  <other_outcome>
    <measure>HIV and PrEP knowledge</measure>
    <time_frame>within six months from randomization</time_frame>
    <description>The HIV and PrEP knowledge retained by participants</description>
  </other_outcome>
  <other_outcome>
    <measure>HIV and MSM stigma</measure>
    <time_frame>within six months from randomization</time_frame>
    <description>Stigma related to HIV and men who have sex with men (MSM) reported by participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Risk perception</measure>
    <time_frame>within six months from randomization</time_frame>
    <description>The risk perception reported by participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Self-efficacy</measure>
    <time_frame>within six months from randomization</time_frame>
    <description>The self-efficacy reported by participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Social support</measure>
    <time_frame>within six months from randomization</time_frame>
    <description>The social support reported by participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Alcohol and substance use</measure>
    <time_frame>within six months from randomization</time_frame>
    <description>The alcohol and substance usage reported by participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Condomless anal sex</measure>
    <time_frame>within six months from randomization</time_frame>
    <description>A dichotomous measure (yes/no) of whether a participant engaged in condomless anal sex</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hiv</condition>
  <arm_group>
    <arm_group_label>CHALO! 2.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MSM randomized to this arm will receive twice weekly digital media messages for 12 weeks about HIV, HIV-testing, prevention, and treatment. Digital contents and components will target SEM/IMB domains. Digital media will combine text messages, infographics, and brief animated videos (&lt;30 seconds), with each message containing a link to a study-specific webpage listing testing resources and MSM-specific services offered by HST. Participants will also be able to interact with online outreach workers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Attention-matched control (AMC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MSM randomized to the AMC arm will receive twice weekly digital media messages for 12 weeks about general health. Digital media will contain a link to a study-specific webpage listing testing resources and MSM-specific services offered by HST. Participants will also be able to interact with online outreach workers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Digital coupon only control (DCO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MSM randomized to the DCO arm will receive, at study entry, a digital coupon for free HIV testing and a resource webpage link.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CHALO! 2.0</intervention_name>
    <description>The components of the intervention are:&#xD;
Contents of digital-media (sent twice/week for 12 weeks) on the following topics: HIV testing, prevention, treatment, linkage-to-care; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers.</description>
    <arm_group_label>CHALO! 2.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Attention-matched control (AMC)</intervention_name>
    <description>The components of the intervention are:&#xD;
Contents of digital-media (sent twice/week for 12 weeks) only related to general health information; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers.</description>
    <arm_group_label>Attention-matched control (AMC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Digital coupon only (DCO)</intervention_name>
    <description>The components of the intervention are:&#xD;
Digital coupon for free HIV testing; Webpage listing testing/ care sites; access to online outreach workers.</description>
    <arm_group_label>Digital coupon only control (DCO)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  live or work in Mumbai or Thane&#xD;
&#xD;
          -  fluent in Hindi or English&#xD;
&#xD;
          -  have had anal sex with men in the past one year&#xD;
&#xD;
          -  report that they have either never been tested for HIV, are unaware of HIV test&#xD;
             results, or are HIV-negative with last HIV test greater than or equal to six months&#xD;
             ago, and have engaged in anal sex since last HIV test&#xD;
&#xD;
          -  able to provide and verify a WhatsApp mobile number and email address&#xD;
&#xD;
          -  willing to answer online surveys for 18 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  participating in a concurrent HIV-related study&#xD;
&#xD;
          -  intention to move out of the Mumbai metropolitan area in the next six months&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Self-identified cis-gendered men</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viraj V Patel, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor, Division of General Internal Medicine, Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Research Coordinator</last_name>
    <phone>9788066641</phone>
    <email>nikhil.chopra@einsteinmed.org</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV screening</keyword>
  <keyword>HIV testing</keyword>
  <keyword>HIV prevention</keyword>
  <keyword>HIV linkage to care</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Only de-identified IPD with ethical approvals from both P.I. and requester.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

